Leqvio™ (inclisiran) is a Prescription Medicine and is supplied as a pre-filled syringe containing 1.5 mL of solution containing 284 mg inclisiran (equivalent to 300 mg inclisiran sodium). LEQVIO™ is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults. Leqvio™ is an unfunded medicine and a prescription charge may apply. For further information about Leqvio™ and its risks and benefits, refer to the Consumer Medicine Information [CMI] at www.medsafe.govt.nz. Ask your doctor if Leqvio™ is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional. Leqvio™ is the registered trademark of Novartis AG. Novartis New Zealand Limited, Auckland

LEQVIO is given as an injection and will be administered by your healthcare professional.